Sign In
Buy BMY
$56.60
+1.88 (+3.44%)
At Close: Jun 04, 2026
Bristol Myers says it needs another year to hit target for new drugs
07:02am, Thursday, 26'th Oct 2023
Drugmaker Bristol Myers Squibb on Thursday pushed back by a year the time frame for its current new-product portfolio to hit $10 billion in sales as the ramp-up of new drugs including anemia treatment
10 Dividend Growth Stocks For October 2023
12:58am, Thursday, 26'th Oct 2023
In this series, I rank a selection of Dividend Radar stocks and present the ten top-ranked stocks for further research and possible investment. I screened for high-quality stocks with superior growth
META Up +4% on +23% Revenue Growth; IBM and NOW Also Beat
07:32pm, Wednesday, 25'th Oct 2023
The social media leader posted a big beat on earnings -- $4.39 per share versus expectations of $3.62 and the year-ago number of $1.64 per share.
This Artificial Intelligence (AI) Stock Is Powering the Biotech Revolution: Should You Invest?
06:50am, Wednesday, 25'th Oct 2023
Schrödinger has a physics-based platform that helps accelerate drug discovery. The company sells its software to other businesses and has its own drug pipeline.
What's in Store for Bristol-Myers (BMY) in Q3 Earnings?
10:34am, Monday, 23'rd Oct 2023
Investors are likely to focus on Opdivo's demand along with an incremental contribution from newer drugs when Bristol-Myers (BMY) reports Q3 results.
Bristol-Myers Squibb Acquisition Of Mirati Makes Sense
08:53am, Sunday, 22'nd Oct 2023
Bristol Myers Squibb is a large pharmaceutical company with a strong dividend yield and impressive assets. The company's recent acquisition of Mirati Therapeutics, including its oncology drug Krazati,
Top Wall Street analysts favor these five dividend stocks during tumultuous times
07:02am, Sunday, 22'nd Oct 2023
TipRanks' analyst ranking service pinpoints Wall Street's best-performing stocks, including Cisco and Chesapeake Energy.
Bristol-Myers Squibb: Time To Get Greedy
10:24am, Saturday, 21'st Oct 2023
Buying Bristol-Myers now could be a practical application of Buffett's advice to be greedy when others are fearful. As it stands right now, the pharmaceutical giant is highly concentrated on just thre
Bristol Myers' (BMY) Opdivo SC Meets Kidney Cancer Study Goals
06:46am, Friday, 20'th Oct 2023
Bristol Myers' (BMY) subcutaneous formulation of Opdivo, developed using Halozyme's Enhanze technology, meets noninferiority goals in a late-stage kidney cancer study compared with intravenous Opdivo.
7 Healthcare Stocks That Can Cure a Lackluster Portfolio
04:11pm, Thursday, 19'th Oct 2023
This hasn't been a great year for healthcare stocks. The Dow Jones U.S. Health Care Index is down 4% on the year compared to a 14% gain in the S&P 500 index.
3 Things About Bristol Myers Squibb That Smart Investors Know
09:53am, Thursday, 19'th Oct 2023
Bristol Myers Squibb is looking at its second consecutive year of declining revenue. It is building a pipeline to stem that decline, resulting from patent expirations.
Could Bristol Myers Squibb Stock Help You Become a Millionaire?
09:15am, Thursday, 19'th Oct 2023
The pharmaceutical giant's top drugs are facing patent cliffs over this decade. However, its new drugs are growing and could generate $25 billion in revenue.
Bristol Myers's injectable kindey cancer drug found non-inferior to IV form
07:11am, Thursday, 19'th Oct 2023
Bristol Myers Squibb said on Thursday its injectable form of blockbuster cancer drug Opdivo was found to be non-inferior to the approved intravenous form in a late-stage trial for treatment of a type
2 Biotech Stocks That Could Make You Richer
10:07am, Tuesday, 17'th Oct 2023
Bristol Myers is turning to acquisitions and its pipeline to offset a major patent cliff. Novartis just completed a spinoff that should lead to stronger overall growth.
Is Bristol Myers Squibb Stock a Buy Now?
07:00am, Friday, 13'th Oct 2023
Bristol Myers' revenue has been falling as its key drugs lose patent protection. The company is relying on new drugs and acquisitions to bolster its portfolio.
